Because anti-VEGF treatment is potentially required for years, each intravitreal injection poses a risk of uveitis, postinjection endophthalmitis, retinal tear or detachment, vitreous hemorrhage, sustained elevated intraocular pressure, cataract progression, pain, and vitreous floaters [17, 18]. Here, VEGFA is linked to uveitis.